Skip to main content
Premium Trial:

Request an Annual Quote

John Crison

Premium
John Crison has Joined Simulations Plus as its director of life sciences.
The company, which offers simulation and modeling software for pharmaceutical discovery and development, announced that Crison replaces Michael Bolger, who has “served the company very well” for 11 years.
 
However, Bolger moved 350 miles from company offices in Lancaster, which was no longer in line with company needs.
 
”The telecommuting arrangement worked well when the team was smaller, but with our rapidly growing team here in Lancaster, he [Michael Bolger] and I agreed that we needed an on-site director,” said CEO Walt Woltosz in a statement.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.